Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,806.40
(
0.76%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.43
(
0.24%
)
Bitcoin
81,150.20
(
0.12%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: goodJohnhunting post# 166219

Monday, 03/10/2014 6:42:07 PM

Monday, March 10, 2014 6:42:07 PM

Post# of 347009
almost there GJH, just a little bit more leg work for Peregrine and it will hopefully be a fact that targeting PS helps just about every auto immune disease to oncology to alzheimers to just about everything.... "astronomical" comes to mind.

Sounds like the "Notch Signaling" pathway will come into play and remember, Peregrine KOL Dmitry Gabrilovich will be in Greece talking just that... re: Notch signaling...

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=95547560&txt2find=notch|signaling

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote